In my first blog of this series, titled Pharma Lifecycle Plagued with Integration and Data Management Challenges (Part I - Overview), I outlined six phases of the pharma lifecycle and set the stage to provide deeper insights into the integration and data management challenges each phase faces. The first stage I'd like to tackle in depth is Research and Development (R&D), which broadly covers drug research and discovery.
Pharma Lifecycle Plagued with Integration and Data Management Challenges (Part II - Research & Development)
Data security is not optional. Organizations owe it to their clients to protect sensitive client data. And market forces in the form of reputation damage, revenue loss, and hefty fines (for regulated data) ensure that there is plenty of incentive to do so.
As organizations move to address increasingly sophisticated security threats, they are often caught off guard by the many hidden costs of security and compliance, realizing (too late) that safeguarding data from current and future threats is more resource-intensive than first imagined—and is growing more so with each passing day.
If the lives of transplant patients didn’t matter, you wouldn’t do what you do. Tireless devotion to finding new treatments, providing close care and monitoring, and extending even the smallest of comforts at the times of greatest need are things you do because it's important to your patients—and to you.
As a transplant professional you would give even more if you could. I know because I used to be one.
During my time as BMT coordinator at Huntsman Cancer Hospital, I was completely immersed in this world.
Big forces in the marketplace – big data, the move to the cloud, the deconstruction of ERP systems, and the growing number of on-premises and cloud-based applications – are compelling many enterprises to rethink their integration strategies. One approach, Integration Platform as a Service (iPaaS), is gaining momentum. But don’t look for iPaaS to offer the best path to the future for all enterprises. Look to Liaison’s ALLOY Platform, the first Data Platform as a Service (dPaaS), instead. Here’s five reasons why:
"What do you know about the platoon, LT?" (Pronounced ell tee.)
Those were the first words my platoon sergeant said (in his thick Boston accent) when I got to my initial assignment as a brand new, squeaky shiny second lieutenant at Fort Drum, New York. The question caught me off guard. I knew nothing. I was only six months out of college and I was now responsible for the health, welfare, morale and mission of a 30-man platoon in an Army Light Infantry Division. My platoon sergeant had a wealth of experience and knowledge compiled from over 15 years of military service around the world; me, four months of ‘book knowledge’ in a sterile classroom. As any young military officer finds out quickly, there is a big difference between book smarts and street smarts.
The unveiling of the Tesla Model 3 has completely disrupted the electric car market and even the automobile industry as a whole. Designed to be the first electric car for the masses, if Elon Musk has his way, the Model 3 will become the catalyst that finally turns electric cars mainstream.
As an executive, how comfortable are you with the security of the sensitive data that your company is responsible for? As your company adopts new, emerging and disruptive technologies, your valuable data assets become increasingly decentralized moving from software to software or from company to external party leading to inherent risks in security and compliance. Most companies and their executives assume these risks have been addressed in their contractual agreements; however, who maintains the inventory of which data is going where? How do you ensure appropriate safeguards or compliance when your partner or service provider utilizes external parties as well?
We had a fantastic time exhibiting at BMT Tandem Meetings 2016 last month. It was a well-organized event that featured informative sessions, a bustling exhibit hall, engaged attendees... oh, and did I mention it was in Hawaii?
At our booth, there were two hot topics of conversation. The first was our creative (and slightly disturbing) IV blood bag giveaway. These attention-getting cold packs were a big hit with attendees, sparking many fun conversations—and even making a debut on Twitter (thanks Jim Omel!).
The setting could not have been better: South Beach Miami, a full moon, and the SCOPE Summit for Clinical Ops Executives, which delivered on its promise to offer “three stimulating days of in-depth discussions focused on issues related to each aspect of clinical trial planning and management.”
Imagine a world where your organization enjoys all the benefits of today’s hybrid enterprise-wide integration—real-time data insights seamless partner collaboration, faster time to market, efficient supply chain operations, and highly satisfied customers—without any investment in on-premises integration middleware, hardware, or IT personnel. A world where, like magic, your data is always where you need it to be, when you need it be there.